FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma
Digestive and Liver Disease · 2026-06 · 58 (6) · 765-772
DOI: 10.1016/j.dld.2026.04.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2026-06. Verfasst von David Tougeron und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Poitiers University Hospital and Poitiers University, Poitiers, France. Electronic address: david.toug…. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Pyrrolidines. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals USA Inc, Ligue Contre le Cancer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology and Gastroenterology, Poitiers University Hospital and Poitiers University, Poitiers, France. Electronic address: david.tougeron@chu-poitiers.fr.
- Departamento de Oncología Médica, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
- Medical Oncology Department. Hospital Clinico Universitario de Valencia, INCLIVA Biomedical Research Institute, Valencia, Spain.
- Fédération Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, Université Bourgogne Europe, Dijon, France.
- Department of digestive oncology, Toulouse University hospital and Toulouse University, Toulouse, France.
- Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.
Förderung
- Takeda Pharmaceuticals USA Inc
- Ligue Contre le Cancer
Zitieren
APA
Tougeron, D., Rivera, F., Kanonnikoff, T. F., Le Malicot, K., Guarssifi, M., Fares, N., Soularue, E., Dos Santos, M., Wagner, M., Taieb, J., Aparicio, T., Laurent-Puig, P., Hacker, U. T., Fernández Montes, A., Al-Batran, S. E., & Lordick, F. (2026). FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma. Digestive and Liver Disease, 58(6), 765-772. https://doi.org/10.1016/j.dld.2026.04.004
Vancouver
Tougeron D, Rivera F, Kanonnikoff TF, Le Malicot K, Guarssifi M, Fares N, et al. FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma. Digestive and Liver Disease. 2026;58(6):765-772. doi:10.1016/j.dld.2026.04.004
BibTeX
@article{Tougeron2026,
author = {Tougeron, David and Rivera, Fernando and Kanonnikoff, Tania Fleitas and Le Malicot, Karine and Guarssifi, Meriem and Fares, Nadim and Soularue, Emilie and Dos Santos, Melanie and Wagner, Mathilde and Taieb, Julien and Aparicio, Thomas and Laurent-Puig, Pierre and Hacker, Ulrich T and Fernández Montes, Ana and Al-Batran, Salah-Eddin and Lordick, Florian},
title = {FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma},
journal = {Digestive and Liver Disease},
year = {2026},
volume = {58},
number = {6},
pages = {765--772},
doi = {10.1016/j.dld.2026.04.004}
}
EUVIMED